Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06046066 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of NM6603 in Advanced Solid Tumors
A Phase 1 study of Cancers, sponsored by NucMito Pharmaceuticals Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT06046066 is a Phase 1 study of Cancers that is actively recruiting participants, run by NucMito Pharmaceuticals Co.. The registered enrollment target is 36 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT06046066, a Phase 1 study of Cancers, is actively recruiting participants, sponsored by NucMito Pharmaceuticals Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is to assess the MTD and RP2D of NM6603 in adult patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG NM6603
Study Locations (4)
Michigan
- Karmanos Cancer Institute - Detroit
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Tennessee
- Tennessee Oncology, PLLC - Nashville
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06046066
The ClinicalTrials.gov registry entry for NCT06046066 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NucMito Pharmaceuticals Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancers appearing as the primary indexed condition, and to 1 intervention - of which NM6603 is the first listed.
NCT06046066 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Michigan, Ohio, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06046066 about?
NCT06046066 is a clinical study titled "A Phase 1 Study of NM6603 in Advanced Solid Tumors". This study is to assess the MTD and RP2D of NM6603 in adult patients with advanced solid tumors.
What is the current status of trial NCT06046066?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-08-31. Estimated completion is 2026-02-28.
What conditions does trial NCT06046066 study?
This clinical trial studies the following conditions: Cancers.
What interventions are being tested in trial NCT06046066?
The interventions under investigation include: NM6603 (DRUG).
Who is sponsoring clinical trial NCT06046066?
This trial is sponsored by NucMito Pharmaceuticals Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06046066 being conducted?
This trial has 4 study locations across Michigan, Ohio, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.